Inidascamine (; developmental code names RL-007, FSV7-007) is an experimental drug which is under development for the treatment of cognitive impairment associated with schizophrenia (CIAS).Donello JE, Walker GA, Schweighoffer F, and Pando MP. Abstract Number: 149. RL-007, a novel oral neuromodulator, enhances synaptic plasticity and cognition in non-clinical models. American College of Neuropsychopharmacology (ACNP) annual meeting. December 5, 2023. https://ir.atai.life/static-files/06c60339-e93c-42fc-9323-c0e38e83f86e It is taken orally. The drug is said to act on the cholinergic, NMDA, and GABAB receptor systems. Inidascamine is being developed by Recognify Life Sciences and atai Life Sciences. It was discovered via screening of compounds for effects on synaptic plasticity and cognition. The drug shows structural similarities to phenethylamines and amphetamines.
See also List of investigational antipsychotics List of investigational cognition and memory disorder drugs
References